

April 16, 2021

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Disclosure of “Names of Drug Product Manufacturers” for Products that KYOSOMIRAI PHARMA Holds Marketing Approvals

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka; hereinafter "KYOSOMIRAI PHARMA"), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has disclosed information on “names of drug product manufacturers” for products that KYOSOMIRAI PHARMA holds marketing approvals of on its website for healthcare professionals (<http://www.kyosomirai-p.co.jp/medical/top.html> (Japanese only)).

KYOSOMIRAI PHARMA has already disclosed “names of countries where active substances are manufactured” for products that KYOSOMIRAI PHARMA holds marketing approvals on the website for healthcare professionals. In response to strong request from healthcare professionals for information on “names of drug product manufacturers,” KYOSOMIRAI PHARMA has decided to make the information available on the website, which allows more healthcare professionals to check the names of drug product manufacturers for the use of KYOSOMIRAI PHARMA’s products with greater reliability.

We strive to appropriately deliver drug information in response to healthcare professionals’ requests.